GlassScriptPhysician profile
Tarun Bhargava
NPI 1952527442
$533,797.55
in general payments reported to CMS, 2019-2025
19 companies · $45K in 2025
The $45K reported for 2025 was more than what 88% of Adult Reconstructive Orthopaedic Surgery providers received nationally (typical 2025 total: $1,425).
See the full distribution for Adult Reconstructive Orthopaedic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102K · 2020: $77K · 2021: $55K · 2022: $65K · 2023: $131K · 2024: $59K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $149K · Royalty Or License: $59K · Travel and Lodging: $23K · Food and Beverage: $3,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $149,012.50 |
| Royalty Or License | $58,998.97 |
| Travel and Lodging | $22,677.18 |
| Food and Beverage | $3,515.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Encore Medical, LP | $473,886.77 | 2019-2025 | Djo Surgical |
| Orthalign INC | $45,193.14 | 2019-2025 | Orthalign Plus |
| Innovation Technologies INC | $11,451.91 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $1,153.84 | 2023-2024 | Iovera, Exparel, Zilretta |
| Stryker Corporation | $1,136.92 | 2019-2025 | 1788 |
| Conformis, INC. | $222.97 | 2021 | |
| Anika Therapeutics, INC. | $200.43 | 2021 | |
| Medacta USA, INC. | $167.54 | 2023-2025 | Gmk Sphere, Amistem |
| Pacira Therapeutics, INC. | $73.21 | 2020-2021 | |
| Avanos Medical | $72.66 | 2023-2025 | On-Q Pump and Accessories, Pnb and Accessories |
| Ferring Pharmaceuticals INC. | $58.19 | 2019-2023 | Euflexxa |
| Ethicon US, LLC | $36.48 | 2019-2025 | Megadyne |
| Bioventus LLC | $31.23 | 2019 | |
| Fidia Pharma USA INC. | $28.38 | 2019 | |
| Restor3d, INC. | $27.81 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $20.26 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $18.31 | 2024 | |
| Organogenesis INC. | $17.50 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,491,638.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarun Bhargava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.